In response to mounting criticism, the National Institutes of Health posted data that shows an improvement in the reporting of results from clinical trials sponsored by the agency.
In fiscal year 2022, 41% of trial results were submitted to the ClinicalTrials.gov federal database, compared with 34% in the previous year and just 29% in fiscal year 2020. In fact, the vast majority of results — 96%, on average — were eventually submitted to the database. But results for most of the trials were late, with just over one-third submitted by the obligatory due dates.
In discussing the findings, Mike Lauer, the deputy director for extramural research, wrote in a March 24 blog post that a recently enacted agency policy designed to improve the reporting of trial results is proving effective. But he also conceded the NIH still has “work to do to increase timely compliance,” and that enforcement actions against wayward trial sponsors will be taken “if needed.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect